Safety Alerts & Recalls

What does this mean?

Following the FDA's detailed review of Spiriva safety data, patients treated with Spiriva do not need to worry about an added risk of stroke or heart attack. If you have any questions about the FDA's review of this safety issue, or if you have concerns about side effects from Spiriva, please follow up with your doctor or other healthcare provider.

Follow-Up to the FDA Safety Review of Tiotropium (marketed as Spiriva Handihaler)

The U.S. Food and Drug Administration (FDA) announced that data from a recent review of Spiriva show no increased risk of stroke, heart attack, or death in patients using the medicine.

Spiriva contains the active ingredient tiotropium, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD). COPD is a serious and chronic lung disease that restricts air flow in the lungs resulting in shortness of breath. In the United States, COPD includes two main conditions - emphysema and chronic bronchitis.

For more information, please visit: more information here

Source: FDA
Publication Date: 2010-01-15
Last Updated: 2010-01-15

Visit the medication page for the following drugs:

Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.